X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PLN-74809 (bexotegrast) is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins, which is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
PLN-74809 (bexotegrast) is an oral, small molecule, dual-selective inhibitor of the αvβ6 and αvβ1 integrins. It is being evaluated in phase 2 clinial trials for the treatment of primary sclerosing cholangitis & suspected moderate to severe liver fibrosis.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2024
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2023
Details:
PLN-74809 (bexotegrast), is an oral small molecule dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC.
Lead Product(s): Bexotegrast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
The new strategy focusing on a limited number of therapeutic areas, to divest clinical NASH assets and, as a result, to discontinue the development of PLN-1474, a small molecule selective inhibitor of integrin αvß1, for the treatment of liver fibrosis associated with NASH.
Lead Product(s): PLN-1474
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PLN-1474
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination February 17, 2023
Details:
PLN-101095, a small molecule, which targets αvβ8 and αvβ1 integrins expressed in the tumor microenvironment, regulating TGF-β activation with the goal of re-sensitizing tumors to PD(L)-1 inhibitors.
Lead Product(s): PLN-101095
Therapeutic Area: Oncology Product Name: PLN-101095
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
Pliant intends to use the net proceeds to develop its ongoing and future preclinical and clinical programs including PLN-74809 (bexotegrast) and PLN-101095, further develop its integrin targeting platform, to fund working capital and for other general corporate purposes.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $287.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 27, 2023
Details:
Pliant intends to use the net proceeds to develop its ongoing and future preclinical and clinical programs including PLN-74809 (bexotegrast) and PLN-101095, further develop its integrin targeting platform, to fund working capital and for other general corporate purposes.
Lead Product(s): Bexotegrast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PLN-74809
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $250.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
